SCHEMBL14643164

SCHEMBL14643164

CCOC(=O)CNC(=O)NCCc1csc(N)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.47
PPID Q08752 3/20 0.47
PPIB P23284 1/20 0.47
PPIA P62937 1/20 0.47
PPIG Q13427 1/20 0.47
ALDH1A1 P00352 3/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
NPC1 O15118 2/20 0.45
MAPT P10636 2/20 0.45
RAB9A P51151 2/20 0.45
HSD17B10 Q99714 2/20 0.42
TSHR P16473 1/20 0.42
KDM4E B2RXH2 1/20 0.42
HPGD P15428 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
GABRA5 P31644 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12643838 0.89 PPID (0.56) LMNAPPIDPPIBPPIAPPIG
SCHEMBL1081996 0.79 MEN1 (0.54) ALDH1A1MEN1KMT2ANPC1MAPT
SCHEMBL27408432 0.77 ALDH1A1 (0.51) ALDH1A1MEN1KMT2ANPC1MAPT
SCHEMBL8445 0.76 MEN1 (0.64) LMNAALDH1A1MEN1KMT2ANPC1
SCHEMBL30191663 0.76 HSD17B10 (0.51) ALDH1A1MEN1KMT2ANPC1MAPT
Bromide SCHEMBL7138577 0.76 ALDH1A1 (0.50) ALDH1A1MEN1KMT2ANPC1MAPT
SCHEMBL12643826 0.75 POLB (0.53) PPIDPPIBPPIAPPIGALDH1A1
SCHEMBL2039512 0.75 MEN1 (0.48) LMNAPPIDPPIBPPIAPPIG
SCHEMBL308007 0.74 GABRA5 (0.44) ALDH1A1NPC1MAPTRAB9AHSD17B10
SCHEMBL14617760 0.73 PPID (0.56) LMNAPPIDPPIBPPIAPPIG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2516387-B1 INHIBITORS OF CYCLOPHILINS FOR USE IN THE PREVENTION AND/OR THE TREATMENT OF VIRAL PATHOLOGIES OR INFECTIONS INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECH MÉDICALE (INSERM) (FR) 2018-02-21 EP disclosed
US-8901295-B2 Inhibitors of cyclophilins and uses thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2014-12-02 US disclosed
US-8802666-B2 Inhibitors of cyclophilins and uses thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2014-08-12 US disclosed
US-20140179687-A1 New Inhibitors of Cyclophilins and Uses Thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2014-06-26 US disclosed
US-20130018044-A1 NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2013-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179687-A1 New Inhibitors of Cyclophilins and Uses Thereof FKBP3, FKBP4, FKBP5 LMNA 4126/4885PPID 73/4885PPIB 51/4885
US-20130018044-A1 NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF FKBP3, FKBP4, FKBP5 LMNA 4126/4885PPID 73/4885PPIB 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.